Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1732885 | 1.00 | CYP1A2 (0.33) | CYP1A2CYP2D6GRM2GRM3MEN1 | |
| SCHEMBL1733291 | 1.00 | CYP1A2 (0.33) | CYP1A2CYP2D6GRM2GRM3MEN1 | |
| SCHEMBL28392033 | 0.83 | GRM2 (0.31) | CYP1A2GRM2GRM3MEN1KMT2A | |
| Ibrotamide SCHEMBL1641878 | 0.78 | EPHX1 (0.31) | — | |
| SCHEMBL2730980 | 0.73 | — | — | |
| SCHEMBL31430102 | 0.72 | SLC22A6 (0.31) | CYP1A2MEN1KMT2AALDH1A1THRB | |
| SCHEMBL9952000 | 0.69 | ALDH1A1 (0.33) | CYP1A2CYP2D6MEN1KMT2AALDH1A1 | |
| SCHEMBL3922345 | 0.69 | ALDH1A1 (0.33) | CYP1A2CYP2D6MEN1KMT2AALDH1A1 | |
| SCHEMBL2303259 | 0.69 | ALDH1A1 (0.33) | CYP1A2CYP2D6MEN1KMT2AALDH1A1 | |
| SCHEMBL2233286 | 0.69 | ALDH1A1 (0.33) | CYP1A2CYP2D6MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2399902-B1 | PROCESS FOR PREPARING 2,3-DI-NON-STRAIGHT-ALKYL-2-CYANO SUCCINIC ACID DIESTERS | CHINA PETROLEUM & CHEMICAL (CN) | 2014-11-26 | — | — | EP | claimed |
| EP-2882738-B1 | NEW ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-05-31 | — | — | EP | disclosed |
| EP-2882739-B1 | NEW ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-05-03 | — | — | EP | disclosed |
| US-9315522-B2 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-19 | — | — | US | disclosed |
| US-9296760-B2 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-29 | — | — | US | disclosed |
| US-20150225424-A1 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-13 | — | — | US | disclosed |
| US-20150210719-A1 | ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND US (IE) | 2015-07-30 | — | — | US | disclosed |
| EP-2882739-A1 | NEW ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland UC (IE) | 2015-06-17 | — | — | EP | disclosed |
| EP-2882738-A1 | NEW ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland UC (IE) | 2015-06-17 | — | — | EP | disclosed |
| US-RE45183-E1 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| EP-0882024-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | Abbott Laboratories (US) | 1998-12-09 | — | — | EP | disclosed |
| EP-0876353-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | Abbott Laboratories (US) | 1998-11-11 | — | — | EP | disclosed |
| US-5693657-A | USEFUL FOR TREATING HYPERCHOLESTEROLEMIA OR ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5646170-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1997021685-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-06-19 | — | — | WO | disclosed |
| WO-1997021683-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-06-19 | — | — | WO | disclosed |
| EP-0684945-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1995-12-06 | — | — | EP | disclosed |
| US-5441975-A | Anticholesterol agent | WARNER-LAMBERT COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| US-5366987-A | Enzyme inhibitors, anticholesterol | WARNER-LAMBERT COMPANY (US) | 1994-11-22 | — | — | US | disclosed |
| WO-1994019330-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210719-A1 | ANTIBACTERIAL COMPOUNDS | FAR1, GAA, ECI1 | CYP1A2 427/4885CYP2D6 310/4885GRM2 4849/4885 |
| US-20150225424-A1 | Antibacterial compounds | FAR1, GAA, ECI1 | CYP1A2 427/4885CYP2D6 310/4885GRM2 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.